Latest news

• Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

  Pear Therapeutics is a pioneer of so-called digital therapeutics, having gained the first ever such approval from the FDA in 2017, for its treatment for patients with Substance Use Disorder ... Like a drug filing with the FDA, Pear Therapeutics is

• FDA clears Sandoz and Pear’s Opioid Use Disorder app

  Its partnership with Pear Therapeutics reflects the growing need for pharma companies to go 'beyond the pill' and offer health systems and patients support in staying on their medication. ... Pear Therapeutics’ solution is modelled on the Community

• Sandoz targets digital therapeutics

  Partners with Pear Therapeutics to launch FDA-approved apps. Novartis’ generics and biosimilar division Sandoz has partnered with Pear Therapeutics to commercialise two mobile phone applications, reSET and reSET-O. ... Corey McCann, president and chief

• Novartis plans digital therapeutics for schizophrenia and MS

  The work will see the Swiss pharma company partner with Pear Therapeutics, a leading light in the emerging digital therapeutics field. ... Novartis said its collaboration with Pear Therapeutics would see the partners work to “better address the full

• Roche and J&J picked for ‘revolutionary’ digital health pilot

  Just nine firms were picked for the pilot: Apple, Fitbit, J&J, Pear Therapeutics, Phosphorus, Roche, Samsung, Tidepool and Verily.